This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miller, V. A. Articles by Kris, M. G. Search for Related Content PubMed PubMed Citation Articles by Miller, V. A. Articles by Kris, M. G. Social Bookmarking                            What's this?

Phase II Trial of Docetaxel and Vinorelbine in Patients With Advanced Non–Small-Cell Lung Cancer

From the Thoracic Oncology Service, Division of Solid Tumor Oncology, and Departments of Medicine and Radiology, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, NY.

Address reprint requests to Vincent A. Miller, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; email millerv{at}mskcc.org

PURPOSE: Docetaxel and vinorelbine are active agents in advanced non–small-cell lung cancer (NSCLC) and demonstrate preclinical synergism perhaps, in part, through their inactivation of the proto-oncogene bcl-2. We show that docetaxel (60 mg/m²) and vinorelbine (45 mg/m²) can be safely combined when given on an every 2-week schedule with filgrastim, with encouraging antitumor activity observed.

PATIENTS AND METHODS: Thirty-five chemotherapy naïve patients with advanced NSCLC received vinorelbine as an intravenous push immediately followed by docetaxel as a 1-hour intravenous infusion once every 2 weeks. Prophylactic corticosteroids, ciprofloxacin, and filgrastim were used.

RESULTS: We delivered median doses of 450 mg/m² of vinorelbine and 600 mg/m² of docetaxel. The major objective response rate was 51% (95% confidence interval [CI], 34% to 68%). With a median follow-up of 14 months, the predicted median survival time was 14 months, and the 1-year survival rate was 60% (95% CI, 44% to 80%). Febrile neutropenia occurred in five patients and five (1.3%) of 384 treatments. No dose-limiting neurotoxicity occurred. Symptomatic onycholysis and excessive lacrimation were observed after several months or more of therapy.

CONCLUSION: Docetaxel 60 mg/m² and vinorelbine 45 mg/m², both given every 2 weeks, is a highly active combination for the treatment of advanced NSCLC. Filgrastim largely obviates neutropenic fever and allows for the single-agent dose-intensity of both drugs to be delivered. The occurrence of certain late toxicities can limit use in some cases and suggests that the combination could also be beneficial in settings requiring briefer, fixed periods of treatment, such as in induction or postoperative therapy.

Presented in part at the Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, May 15-18, 1999.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. A. Limentani, A. M. Brufsky, J. K. Erban, M. Jahanzeb, and D. Lewis Phase II Study of Neoadjuvant Docetaxel, Vinorelbine, and Trastuzumab Followed by Surgery and Adjuvant Doxorubicin Plus Cyclophosphamide in Women With Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancer J. Clin. Oncol., April 1, 2007; 25(10): 1232 - 1238. [Abstract] [Full Text] [PDF]

				M. Johansen, J. Kuttesch, W. A. Bleyer, M. Krailo, M. Ames, and T. Madden Phase I Evaluation of Oral and Intravenous Vinorelbine in Pediatric Cancer Patients: A Report from the Children's Oncology Group Clin. Cancer Res., January 15, 2006; 12(2): 516 - 522. [Abstract] [Full Text] [PDF]

				G. P. Stathopoulos, M. Veslemes, N. Georgatou, D. Antoniou, P. Giamboudakis, K. Katis, D. Tsavdaridis, S. K. Rigatos, I. Dimitroulis, S. Bastani, et al. Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial Ann. Onc., July 1, 2004; 15(7): 1048 - 1055. [Abstract] [Full Text] [PDF]

				V. A. Miller, D. H. Johnson, L. M. Krug, B. Pizzo, L. Tyson, W. Perez, P. Krozely, A. Sandler, D. Carbone, R. T. Heelan, et al. Pilot Trial of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib Plus Carboplatin and Paclitaxel in Patients With Stage IIIB or IV Non-Small-Cell Lung Cancer J. Clin. Oncol., June 1, 2003; 21(11): 2094 - 2100. [Abstract] [Full Text] [PDF]

				R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103. [Abstract] [Full Text] [PDF]

				K. V. Mattson, R. P. Abratt, G. ten Velde, and K. Krofta Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study Ann. Onc., January 1, 2003; 14(1): 116 - 122. [Abstract] [Full Text] [PDF]

				A. Inoue and N. Saijo Recent Advances in the Chemotherapy of Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., July 1, 2001; 31(7): 299 - 304. [Abstract] [Full Text] [PDF]

				F. R. Khuri, J. R. Rigas, R. A. Figlin, R. J. Gralla, D. M. Shin, R. Munden, N. Fox, M. R. Huyghe, Y. Kean, S. D. Reich, et al. Multi-Institutional Phase I/II Trial of Oral Bexarotene in Combination With Cisplatin and Vinorelbine in Previously Untreated Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., May 15, 2001; 19(10): 2626 - 2637. [Abstract] [Full Text] [PDF]

				G. V. Kornek, H. Ulrich-Pur, M. Penz, K. Haider;, W. Kwasny, D. Depisch, E. Kovats, F. Lang, B. Schneeweiss, and W. Scheithauer Treatment of Advanced Breast Cancer with Vinorelbine and Docetaxel With or Without Human Granulocyte Colony-Stimulating Factor J. Clin. Oncol., February 1, 2001; 19(3): 621 - 627. [Abstract] [Full Text] [PDF]